Therapeutic potential of 5-aminolevulinic acid and sodium-ferrous citrate for viral insults: relevance to the COVID-19 crisis

2021 ◽  
Author(s):  
Hideyuki Negoro ◽  
Christos Chatziantonio ◽  
Mohammed S. Razzaque
Keyword(s):  
Aminolevulinic Acid ◽  
Therapeutic Potential ◽  
Ferrous Citrate

scholarly journals Effects of 5-aminolevulinic acid and sodium ferrous citrate on fibroblasts from individuals with mitochondrial diseases

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Masaru Shimura ◽  
Naoko Nozawa ◽  
Minako Ogawa-Tominaga ◽  
Takuya Fushimi ◽  
Makiko Tajika ◽  
...  
Keyword(s):  
Aminolevulinic Acid ◽  
Mitochondrial Diseases ◽  
Ferrous Citrate

scholarly journals The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain

2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Feryal Al-Saber ◽  
Waleed Aldosari ◽  
Mariam Alselaiti ◽  
Hesham Khalfan ◽  
Ahmed Kaladari ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Aminolevulinic Acid ◽  
Antioxidant Properties ◽  
Ferrous Citrate ◽  
Gulf Countries ◽  
Significant Difference ◽  
Patients With Diabetes

Type 2 diabetes mellitus is prevalent especially in Gulf countries and poses serious long-term risks to patients. A multifaceted treatment approach can include nutritional supplements with antioxidant properties such as 5-aminolevulinic acid (5-ALA) with sodium ferrous citrate (SFC). This prospective, randomized, single-blind, placebo-controlled, dose escalating pilot clinical trial assessed the safety of 5-ALA with SFC at doses up to 200 mg 5-ALA/229.42 mg SFC per day in patients living in Bahrain with type 2 diabetes mellitus that was uncontrolled despite the use of one or more antidiabetic drugs. Fifty-three patients (n=53) from 3 sites at one center were enrolled by Dr. Feryal (Site #01), Dr. Hesham (Site #02), and Dr. Waleed (Site #03) (n=35, 5-ALA-SFC;n=18, placebo). There was no significant difference in incidence of adverse events reported, and the most frequent events reported were gastrointestinal in nature, consistent with the known safety profile of 5-ALA in patients with diabetes. No significant changes in laboratory values and no difference in hypoglycemia between patients receiving 5-ALA and placebo were noted. Overall, the current results support that use of 5-ALA-SFC up to 200 mg per day taken as 2 divided doses is safe in patients taking concomitant oral antidiabetic medications and may offer benefits in the diabetic population. This trial is registered with ClinicalTrials.govNCT02481141.

5-Aminolevulinic acid combined with sodium ferrous citrate ameliorates H2O2-induced cardiomyocyte hypertrophy via activation of the MAPK/Nrf2/HO-1 pathway

2015 ◽  
Vol 308 (8) ◽  
pp. C665-C672 ◽  
Author(s):  
Mingyi Zhao ◽  
Huiming Guo ◽  
Jimei Chen ◽  
Masayuki Fujino ◽  
Hidenori Ito ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Natriuretic Peptide ◽  
Aminolevulinic Acid ◽  
Cardiomyocyte Hypertrophy ◽  
Marker Genes ◽  
Heme Oxygenase 1 ◽  
Dependent Manner ◽  
Ros Production ◽  
Ferrous Citrate ◽  
Atrial Natriuretic

Hydrogen peroxide (H2O2) causes cell damage via oxidative stress. Heme oxygenase-1 (HO-1) is an antioxidant enzyme that can protect cardiomyocytes against oxidative stress. In this study, we investigated whether the heme precursor 5-aminolevulinic acid (5-ALA) with sodium ferrous citrate (SFC) could protect cardiomyocytes from H2O2-induced hypertrophy via modulation of HO-1 expression. HL-1 cells pretreated with/without 5-ALA and SFC were exposed to H2O2 to induce a cardiomyocyte hypertrophy model. Hypertrophy was evaluated by planar morphometry, 3H-leucine incorporation, and RT-PCR analysis of hypertrophy-related gene expressions. Reactive oxygen species (ROS) production was assessed by 5/6-chloromethyl-2′,7′-ichlorodihydrofluorescein diacetate acetylester. HO-1 and nuclear factor erythroid 2-related factor 2 (Nrf2) protein expressions were analyzed by Western blot. In our experiments, HL-1 cells were transfected with Nrf2 siRNA or treated with a signal pathway inhibitor. We found several results. 1) ROS production, cell surface area, protein synthesis, and expressions of hypertrophic marker genes, including atrial natriuretic peptide, brain natriuretic peptide, atrial natriuretic factor, and β-myosin heavy chain, were decreased in HL-1 cells pretreated with 5-ALA and SFC. 2) 5-ALA and SFC increased HO-1 expression in a dose- and time-dependent manner, associated with upregulation of Nrf2. Notably, Nrf2 siRNA dramatically reduced HO-1 expression in HL-1 cells. 3) ERK1/2, p38, and SAPK/JNK signaling pathways were activated and modulate 5-ALA- and SFC-enhanced HO-1 expression. SB203580 (p38 kinase), PD98059 (ERK), or SP600125 (JNK) inhibitors significantly reduced this effect. In conclusion, our data suggest that 5-ALA and SFC protect HL-1 cells from H2O2-induced cardiac hypertrophy via activation of the MAPK/Nrf2/HO-1 signaling pathway.

scholarly journals Safety test of a supplement, 5-aminolevulinic acid phosphate with sodium ferrous citrate, in diabetic patients treated with oral hypoglycemic agents

2014 ◽  
Vol 4 (9) ◽  
pp. 415 ◽  
Author(s):  
Naohide Yamashita ◽  
Atai Watanabe ◽  
Hikaru Kondo ◽  
Satofumi Kawata ◽  
Tohru Tanaka ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Adverse Events ◽  
Hemoglobin A1c ◽  
Aminolevulinic Acid ◽  
Fasting Blood Glucose ◽  
Hypoglycemic Agents ◽  
Diabetic Patients ◽  
Oral Hypoglycemic Agents ◽  
Acid Phosphate ◽  
Ferrous Citrate

Objective: This study aimed to examine the safety of 5-aminolevulinic acid phosphate (5-ALA) with sodium ferrous citrate (SFC) in diabetic patients treated with one or more oral hypoglycemic agents (OHAs).Background: Recent intervention studies performed in the USA and Japan have shown that a nutritional supplement of 5-ALA with SFC efficiently reduced blood glucose levels in pre-diabetic population without any adverse events. Thus, it was anticipated that 5-ALA with SFC may potentially be taken as a beneficial supplement by diabetic patients who were being treated with OHA therapy. Nevertheless, it is important to examine its safety and efficacy in diabetic population.Methods: This study was a prospective single-blinded, randomized, placebo-controlled and parallel-group comparison study. Medically treated diabetic patients between the ages of 30 and 75 were recruited from the Tokyo metropolitan area of Japan and 45 subjects were selected after screening. These subjects were randomly assigned to three groups: daily intake of 15mg 5-ALA, 50mg 5-ALA, and a placebo (n=15, respectively). The supplement or placebo was administered for 12 weeks followed by a four week washout period. The primary endpoint was safety and  occurrence of hypoglycemic attack, while the secondary endpoint was changes of fasting blood glucose (FBG) and hemoglobin A1c (HbA1c). Results: Adverse events related to 5-ALA with SFC were not observed in all the groups. Abnormalities in blood and urine tests were not observed either. Significant decrease in FBG was not detected in all the groups. However, there was a small but significant decrease in HbA1c at 4 and 8 week in the 15 mg 5-ALA group. Significant decrease in HbA1c was not observed in the 50 mg 5-ALA group, although a tendency to decrease after 4 weeks was apparent.Conclusion: 5-ALA with SFC is a safe and potentially beneficial supplement if taken by diabetic patients treated with OHAs.Trial registration: UMIN 000008038Key words: type 2 diabetes, 5-aminolevulinic acid (5-ALA), sodium ferrous citrate (SFC), oral hypoglycemic agent (OHA), hemoglobin A1c (HbA1c), fasting blood glucose (FBG)

scholarly journals Safety Assessment of Oral 5-aminolevulinic Acid and Ferrous iron in Healthy Human Subjects: A Non-randomized, Open-label, Non-placebo-controlled Trial

2021 ◽  
Author(s):  
Hidenori Ito ◽  
Tohru Tanaka
Keyword(s):  
Safety Assessment ◽  
Aminolevulinic Acid ◽  
Human Subjects ◽  
Controlled Trial ◽  
Elevated Serum ◽  
Food Supplement ◽  
Open Label ◽  
Healthy Human ◽  
Ferrous Citrate ◽  
Combined Administration

Abstract The combination of 5-aminolevulinic acid (5-ALA) phosphate and sodium ferrous citrate (SFC) has been approved as an ingredient of food supplement in several countries because of its wide applicability to healthcare areas. We aimed to assess the safety of 5-ALA phosphate and SFC in healthy adult subjects at the dose several times higher than that available on market. This was an open, non-randomized, non-placebo-controlled trial that included 11 men and 11 women. Doses of 250 mg 5-ALA phosphate and 143.4 mg SFC (15 mg as Fe) per day were orally administered for 28 days. Blood and urine analyses and interviews were conducted to assess the safety. No test compound-related adverse events or abnormal values were observed, except for elevated serum iron levels, which were mild to moderate and transient. Combined administration of 5-ALA phosphate and SFC to healthy adults is well-tolerated and safe at the dose and duration investigated in this study.

Sign in / Sign up

Export Citation Format

Share Document